{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '8.2', 'Secondary Objectives', '68', '8.3', 'Exploratory Objectives', '68', '9', 'INVESTIGATIONAL PLAN', '69', '9.1', 'Overall Study Design and Plan', '69', '9.2', 'Discussion of Study Design', '71', '9.3', 'Selection of Study Population', '72', '9.3.1', 'Inclusion Criteria', '72', '9.3.2', 'Exclusion Criteria', '73', '9.3.3', 'Removal of Subjects from Therapy or Assessment', '73', '9.3.4', 'Criteria for Responders Who Relapse', '75', '9.3.5', 'Replacement Policy', '75', '9.3.5.1 Subjects', '75', '9.3.5.2 Centers', '75', '9.4', 'Treatments', '75', '9.4.1', 'Treatments Administered', '75', '9.4.2', 'Identity of Investigational Product', '75', '9.4.3', 'Labeling', '76', '9.4.4', 'Storage', '76', '9.4.5', 'Drug Accountability', '76', '9.4.6', 'Study Drug Administration and Timing of Dose for each Subject', '77', '9.4.6.1 Description of Clinical Supplies', '77', '9.4.6.2 Determination of Dose Volume', '77', '9.4.6.3 Details Concerning Timing and Dose Administration', '77', '9.4.6.3.1', 'Preparation and Administration of Teprotumumab', '77', '9.4.6.3.2', 'Dose Modifications, Interruptions, and Delays', '78', '9.4.7', 'Method of Assigning Subjects to Treatment Groups', '79', '9.4.8', 'Masking and Unmasking', '79', '9.4.9', 'Concomitant Therapy and Restricted Medications', '79', '9.4.9.1 Restricted Therapy and Medications', '80', '9.4.10 Treatment Compliance', '81', '9.5', 'Efficacy, Quality-of-Life, Pharmacokinetic, and Safety Variables', '82', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 39 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '9.5.1', 'Efficacy Variables', '82', '9.5.1.1 Proptosis (Exophthalmos)', '82', '9.5.1.2 Clinical Activity Score (CAS)', '82', '9.5.1.3 Clinical Measures of Severity', '83', '9.5.1.3.1', 'Motility Restriction - Details for Measurement', '84', '9.5.2', 'Quality-of-Life Assessment', '85', '9.5.3', 'Pharmacokinetic Measurements', '85', '9.5.4', 'Safety Variables', '85', '9.5.4.1', 'Adverse Events', '85', '9.5.4.1.1', 'Definitions', '85', '9.5.4.1.2', 'Documentation of Adverse Events', '87', '9.5.4.1.3', 'Intensity of Adverse Events', '88', '9.5.4.1.4', 'Relationship to Study Drug', '88', '9.5.4.1.5', 'Reporting and Documenting SAEs', '89', '9.5.4.1.6', 'Follow-Up of Adverse Events', '89', '9.5.4.1.7', 'Medication Error and Overdose', '90', '9.5.4.1.8', 'Review of Adverse Events and Emerging New Safety Information', '90', '9.5.4.1.9', 'Reporting of IND Safety Reports', '90', '9.5.4.1.10', 'Reporting of Suspected Unexpected Serious Adverse Reactions in', 'the EU', '90', '9.5.4.1.11 Development Safety Update Reports', '90', '9.5.4.2 Pregnancy Reporting', '90', '9.5.4.3', 'Vital Signs', '91', '9.5.4.4 Physical and Ophthalmic Examinations, Height, and Weight', '91', '9.5.4.5', 'ECGs', '92', '9.5.4.6', 'Clinical Laboratory Safety Tests', '92', '9.5.4.7', 'Immunogenicity Testing', '93', '9.5.4.8 Data Safety Monitoring Board', '94', '9.5.5', 'Appropriateness of Measurements', '94', '9.5.6', 'Study Procedures', '94', '9.5.6.1 Day 1/Baseline', '94', '9.5.6.2 Week 1', '96', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 40 of 118']\n\n###\n\n", "completion": "END"}